News 2022-08-23
Porton Reports Strong Interim Results 2022
The year 2022 is an important milestone for Porton. Despite of the uncertainties of the external environment, we always keep in mind Porton’s mission of "Enabling public’s early access to good medicines" to overcome those challenges and ensure delivery through an agile and stable management system. In the future, we will maintain keen insights and be more proactive in embracing changes so as to empower our business and help good medicines become accessible to the public earlier.
Others
More
News 2025-04-16
Porton Advanced's End-to-End CDMO Solutions Accelerates IND Approval of Tasly's Innovative Dual-Targeting CAR-T Therapy
April 12, 2025 - Porton Advanced proudly announces its CDMO support for TASLY PHARMACEUTICAL CO., LTD’s Innovative Dual-Targeting CAR-T Therapy, "P134 Cell Injection," which has received Investigational New Drug (IND) approval from China's National Medical Products Administration (NMPA) (Approval No.: 2025LP01030). This breakthrough CAR-T therapy is indicated for recurrent glioblastoma (GBM).
News 2025-04-11
Porton Newsletter - Q1 2025 Recap
Technical Enabling Services & Solutions Company Events ESG Marketing Activities
